Innoviva (INVA) Other Non-Current Assets (2010 - 2026)
Innoviva's (INVA) quarterly Other Non-Current Assets came in at $40.5 million in Q1 2026, down 1.8% YoY from $41.3 million in Q1 2025, and down 0.53% on a QoQ basis from $40.7 million in Q4 2025.
Innoviva (INVA) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Other Non-Current Assets data on file, last reported at $40.5 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 1.8% year-over-year to $40.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.5 million (down 1.8% YoY) and the FY2025 annual result came in at $40.7 million, down 1.77% from the prior year.
- Other Non-Current Assets eased to $40.5 million in Q1 2026, from $40.7 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $41.5 million in Q4 2024 to a low of $313000.0 in Q1 2022.
- A 5-year average of $14.1 million and a median of $3.6 million in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 38981.82% — and 2025, when it slumped 60.71%.
- Tracing INVA's Other Non-Current Assets over 5 years: stood at $4.3 million in 2022, then retreated by 24.01% to $3.3 million in 2023, then surged by 1169.57% to $41.5 million in 2024, then slipped by 1.77% to $40.7 million in 2025, then dropped by 0.53% to $40.5 million in 2026.
- The last three Other Non-Current Assets figures came in at $40.5 million (Q1 2026), $40.7 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 39.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.89 Mn |
| Mar 31, 2026 | 40.53 Mn |
| Dec 31, 2025 | 40.74 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 41.18 Mn |
| Mar 31, 2025 | 41.27 Mn |
| Dec 31, 2024 | 41.48 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.98 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 3.27 Mn |
| Sep 30, 2023 | 3.44 Mn |
| Jun 30, 2023 | 3.56 Mn |
| Mar 31, 2023 | 3.89 Mn |
| Dec 31, 2022 | 4.30 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Mar 31, 2022 | 313,000.00 |
| Dec 31, 2021 | 11,000.00 |
| Sep 30, 2021 | 136,000.00 |